Overview

  • Product nameAnti-Caveolin-1 antibodySee all Caveolin-1 primary antibodies ...
  • Description
    Goat polyclonal to Caveolin-1
  • SpecificityNo cross-reactivity expected to Caveolin-2 and Caveolin-3.
  • Tested applicationsICC/IF, IHC-FoFr, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Dog, Pig
  • Immunogen

    Synthetic peptide corresponding to Human Caveolin-1 aa 33-44 (internal sequence).
    Sequence:

    DELSEKQVYDAH

  • Positive control
    • Human spleen lysate. Lysate from transfected HEK293 cells transiently expressing Caveolin-1.

Properties

Applications

Our Abpromise guarantee covers the use of ab36152 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. See Abreviews.
IHC-FoFr 1/100. PubMed: 18716216
WB Use a concentration of 0.01 - 0.03 µg/ml. Detects a band of approximately 21, 25 kDa (predicted molecular weight: 20 kDa).

Target

  • FunctionMay act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway.
  • Tissue specificityExpressed in muscle and lung, less so in liver, brain and kidney.
  • Involvement in diseaseDefects in CAV1 are the cause of congenital generalized lipodystrophy type 3 (CGL3) [MIM:612526]; also called Berardinelli-Seip congenital lipodystrophy type 3 (BSCL3). Congenital generalized lipodystrophies are autosomal recessive disorders characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
  • Sequence similaritiesBelongs to the caveolin family.
  • Post-translational
    modifications
    The initiator methionine for isoform Beta is removed during or just after translation. The new N-terminal amino acid is then N-acetylated.
  • Cellular localizationGolgi apparatus membrane. Cell membrane. Membrane > caveola. Membrane raft. Colocalized with DPP4 in membrane rafts. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
  • Information by UniProt
  • Database links
  • Alternative names
    • CAV 1 antibody
    • CAV 1 antibody
    • CAV antibody
    • CAV1 antibody
    • CAV1_HUMAN antibody
    • caveolae protein, 22 kD antibody
    • caveolin 1 alpha isoform antibody
    • caveolin 1 beta isoform antibody
    • Caveolin 1 caveolae protein 22kDa antibody
    • Caveolin-1 antibody
    • Caveolin1 antibody
    • cell growth-inhibiting protein 32 antibody
    • MSTP085 antibody
    • OTTHUMP00000025031 antibody
    • VIP 21 antibody
    • VIP 21 antibody
    • VIP21 antibody
    see all

Anti-Caveolin-1 antibody images

  • Anti-Caveolin-1 antibody (ab36152) at 0.3 µg/ml + Human Spleen lysate (35µg protein in RIPA buffer).

    Predicted band size : 20 kDa
    Observed band size : 21,25 kDa (why is the actual band size different from the predicted?)
    Primary incubation was 1 hour. Detected by chemiluminescence.
  • All lanes : Anti-Caveolin-1 antibody (ab36152) at 1 µg/ml

    Lane 1 : HEK293 cell lysate overexpressing Caveolin 1
    Lane 2 : MOCK-transfected HEK293 cell lysate


    Predicted band size : 20 kDa
    Observed band size : 23 kDa (why is the actual band size different from the predicted?)

References for Anti-Caveolin-1 antibody (ab36152)

This product has been referenced in:
  • Hunt CL  et al. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol 85:334-47 (2011). WB ; Human . Read more (PubMed: 21047970) »
  • Schmidtko A  et al. cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci 28:8568-76 (2008). IHC-FoFr ; Mouse . Read more (PubMed: 18716216) »

See all 2 Publications for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (Human umbilical vein endothelial cells)
Specification Human umbilical vein endothelial cells
Fixative Paraformaldehyde
Permeabilization Yes - Saponine 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Prof. JL Balligand

Verified customer

Submitted Apr 16 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Cow Cell (Bovine aortic endothelial cells)
Specification Bovine aortic endothelial cells
Fixative Paraformaldehyde
Permeabilization Yes - Saponin 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Prof. JL Balligand

Verified customer

Submitted Apr 08 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (A7r5 (rat smooth muscle cells))
Specification A7r5 (rat smooth muscle cells)
Fixative Paraformaldehyde
Permeabilization Yes - Saponine 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Prof. JL Balligand

Verified customer

Submitted Mar 24 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"